Oxsedo® 200 mg — A Smarter Evolution in ED Therapy

Misk Pharma proudly unveils Oxsedo® 200 mg, an advanced erectile dysfunction (ED) therapy powered by Udenafil, launched through a strategic partnership with the Korean pharmaceutical leader Dong-A Pharmaceutical.

In a therapeutic area that has seen limited innovation for more than two decades, Oxsedo® represents a meaningful evolution within the PDE-5 inhibitor class. Udenafil is distinguished by its faster onset of action, sustained therapeutic window, and improved tolerability, offering a more balanced and patient-friendly treatment experience compared to conventional ED therapies.

Designed to deliver reliable efficacy with fewer treatment-limiting side effects, Oxsedo® supports rapid responsiveness, longer confidence during intimacy, and better overall adherence, aligning closely with real-world patient needs and expectations.

Manufactured under the highest international quality and safety standards, Oxsedo® 200 mg equips healthcare professionals with a next-generation ED option that combines performance, safety, and patient satisfaction.

Building on its successful launch, Misk Pharma is actively preparing to register and list Oxsedo® across key MENA markets, reinforcing its ambition to establish Oxsedo® as a leading regional reference in modern ED management